When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
A new Virginia law governing collaborations between nurse practitioners and doctors leaves unresolved key legal issues in team-based care, including those pertaining to medical malpractice and liability and anticompetitive practices.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Rachel O. Reid, MD, MS and Ateev Mehrotra, MD, MPH
An effective policy regarding retail clinics in a primary care practice should address patients' need for timely and convenient acute care and build capacity for enhanced access to acute care within the primary care clinic itself.
When ventilator support is being withdrawn from a dying child, responsive titration of sedative medications by the ICU team can relieve suffering without anesthetizing the child completely or hastening death.
Jessie Kimbrough-Sugick, MD, MPH, Jessica Holzer, MA, and Eric B. Bass, MD, MPH
Researchers who approach community partners with an agenda already in hand are missing the point of the community-based participatory research enterprise: developing priorities for study together.
By privileging traditional research methods in forms for research protocol approval, IRBs can unknowingly allow community partners to be harmed in CBPR. Changes to the language can help ensure appropriate sensitivity and community involvement.